SALT LAKE CITY and TORONTO, Feb. 23,
2015 /PRNewswire/ -- EastGate Biotech Corp. (OTCBB:
ETBI), an emerging pharmaceutical company aimed at utilizing drug
delivery innovations in the development of improved novel
formulations and alternative dosage forms of existing biologically
active molecules engages Preferred Nutrition (www.pno.ca) to
distribute the company's nutraceutical and natural consumer
products across Canada.
Preferred Nutrition Inc. is a Canadian premier distribution
company founded in 2002. It primarily distributes to
approximately 1,200 health food stores across Canada. It
represents 5 top product lines for a total of 78 products in the
vitamin and supplement category.
Preferred Nutrition will initially start marketing E-drops which
is a natural and herbal alternative that assists to rid the body of
UTI infections painlessly and effectively without side effects of
synthetic drugs. Preferred Nutrition is also reviewing the
marketing of other EastGate products, such as Vitamin D3 drops,
Glucora, etc.
Information on EastGate's natural product line can be found at
www.nano-essentials.com. Previously, the company announced a
distributor for its nutraceutical product line including E-drops in
the United States under its own
private label.
"We are pleased to have established a distribution relationship
with Preferred Nutrition Inc. as it validates the marketplace's
demand for new and innovative products such as those delivered
through EastGate's proprietary sub-micron self-nanoemulsifying
platform technology," says Anna
Gluskin, EastGate's CEO. "E-drops, which is the first
product that will be launched by Preferred Nutrition, is a unique
product in its classification to aid in the natural elimination of
UTI infections and the company's distribution network will provide
increased visibility to consumers in the growing natural product
marketplace," continues Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact,
contained or incorporated by reference in this news release
constitute "forward-looking information" or "forward-looking
statements" within the meaning of certain securities laws,
including the provisions for "safe harbour" under the United States
Private Securities Litigation Reform Act of 1995 and are based on
expectations, estimates and projections as of the date of this news
release.
The words "anticipates", "plans", "expects", "indicate",
"intend", "scheduled", "estimates", "forecasts", "focus",
"guidance", "initiative", "model", "methodology", "outlook",
"potential", "projected", "pursue", "strategy", "study", "targets",
or "believes", or variations of or similar such words and phrases
or statements that certain actions, events or results "may",
"could", "would", or "should", "might", or "way forward", "will be
taken", "will occur" or "will be achieved" and similar expressions
identify forward-looking statements. Forward-looking statements are
necessarily based upon a number of estimates and assumptions that
are inherently subject to significant business, economic and
competitive risks, uncertainties and contingencies. The risks,
estimates, models and assumptions contained or incorporated by
reference in this release, include those identified from time to
time in the reports filed by EastGate with the SEC, which should be
considered together with any forward-looking statement.
EastGate undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/eastgate-biotech-engages-distribution-company-for-its-nutraceutical-products-for-canadian-market-300039084.html
SOURCE EastGate Biotech Corp.